This week, we have conversations with Phil L’Huillier, CEO of Scancell, and Shai Melcer, head of Israel’s National Bio-Convergence Program.
Interview times:
03:25 Scancell
28:04 National Bio-Convergence Program
Scancell
Scancell recently announced a partnership with the UK’s NHS Cancer Vaccine Launch Pad, enabling fast-tracked access for melanoma patients.
The company’s DNA off-the-shelf cancer vaccine (iSCIB1+) is addressing a critical unmet need in advanced metastatic melanoma. It is currently in phase 2 clinical development with the next key data read outs expected in the middle of this year. Initial phase 2 clinical data showed compelling efficacy: 80% progression free survival in 25 patients at six months with 20% achieving a complete response.
iSCIB1+ activates a strong and safe lasting immune response in patients and is setting a new benchmark in the treatment of advanced melanoma. It offers faster, more cost-effective and conveniently administered therapies, bringing targeted cancer treatments within reach for more patients.
In addition, Modi-1, Scancell’s innovative peptide cancer vaccine, is another key programme. The company saw promising early results from the ModiFY phase 1/2 clinical study. The second stage of the trial is ongoing, with further data readouts expected in H2 2025.
We spoke with Scancell’s CEO, Phil L’Huillier.
Israel’s National Bio-Convergence Program
Our second conversation is with Shai Melcer, head of Israel’s National Bio-Convergence Program. Bio-convergence is an emerging cutting-edge field that combines biology with engineering, AI, nanotechnology, and advanced materials to drive innovation across healthcare, energy, agriculture, food technology, and materials science.
Melcer explains that: “Bio-convergence is the world in which biology meets other technologies from the world of engineering—both hardware and software.”
This fusion is already enabling breakthroughs such as AI-driven drug discovery, bioengineered materials, sustainable biofuels, precision agriculture, and alternative protein production.
In our chat, Melcer discusses how bio-convergence is redefining technological innovation, AI-driven drug discovery, bioengineered materials, sustainable energy, and future food systems, and more.
To get in touch with guest suggestions, please email jim@deeptechdigest.com
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
